Diligence memo · auto-generated · as of July 2, 2026
Cognition Therapeutics Inc
Cognition Therapeutics Inc looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Cognition Therapeutics Inc operates in Biotechnology, based in PITTSBURGH.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Cognition Therapeutics Inc has raised $35M in disclosed capital across 8 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $16M on 2014-03-20.
Most recent recorded round closed around 2018-11-15.
Valuation (modeled)modeled
Provath models Cognition Therapeutics Inc at approximately $65M (range $3.3M–$252M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.08× the median modeled value of Series B Biotechnology companies in 2016–2018 (101 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 9 months.
Last raise 7.6 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.5× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 77% of Biotechnology peers (4293 compared).
Modeled value ranks above 50% of those peers.
Closest niche peers: Liquid BioScience, Inc., Amphivena Therapeutics, Inc., Tracon Pharmaceuticals, Inc., Tetra Discovery Partners, Inc., ECM Therapeutics, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.